Subjects With Moderate to Severe Chronic Plaque Psoriasis. Study of Efficacy and Safety of Adalimumab in Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis Resource links provided by NLM:. Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis (CHAMPION). Psoriasis is a common, chronic, inflammatory skin disease that can have a significant impact on the quality of life of those who are afflicted. Traditional treatments for moderate to severe psoriatic disease include phototherapy, systemic retinoids, methotrexate, and cyclosporine. The results of this phase II study demonstrated the efficacy of adalimumab in the treatment of moderate to severe plaque-type psoriasis. Clinical and histological response of subject in phase II study of adalimumab after 12 weeks.
Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial. M02-538: Phase 2 Study of Two Dosing Schedules of Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis. Safety and effectiveness of adalimumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to prior etanercept. Adalimumab treatment for severe recalcitrant chronic plaque psoriasis.
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis. Full Title of StudyA Phase III, Multicenter Study of the Efficacy and Safety of Adalimumab Treatment in Subjects With Moderate to Severe Chronic Plaque Psoriasis. Adalimumab for Treatment of Moderate to Severe Chronic Plaque Psoriasis of the Hands and Feet: Efficacy and Safety Results From REACH, a Randomized, Placebo-Controlled, Double-blind Trial. (FDA), data on the safety and efficacy of alefacept treatment beyond 2 courses are limited. Psoriasis is a common chronic skin disease characterized by cutaneous inflammation and epidermal hyperproliferation. Both studies evaluated the efficacy and safety of Humira in clearing skin in moderate to severe adult plaque psoriasis patients versus placebo.
Similar Articles For Pubmed (select 20605254)
Study Title: A Phase 3, Multi-Site, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of 2 Oral Doses of CP-690,550 in Subjects with Moderate to Severe Chronic Plaque Psoriasis. Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab. – Results show HUMIRA is safe and effective for the treatment of severe chronic plaque psoriasis in pediatric patients. Additional HUMIRA data to be presented at WCD include poster presentations on moderate to severe plaque psoriasis, including a five-year interim analysis from a 10-year post-marketing surveillance patient registry (ESPRIT) as well as a subgroup analysis evaluating efficacy of HUMIRA across body weight and body mass index in Chinese patients. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. To better understand efficacy and safety, indirect meta-analysis comparing drug-to-drug is required since randomized placebo-controlled trials may not be feasible. C. J. Correr and M. F. Otuki contributed to the elaboration of the study subject, delimitation of the study, interpretation of the results and manuscript review. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.